Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 56
Filter
1.
Int. braz. j. urol ; 47(3): 495-502, May-June 2021. tab, graf
Article in English | LILACS | ID: biblio-1154505

ABSTRACT

ABSTRACT Testicular cancer is considered a rare disease affecting approximately 1% to 2% of the male population. This neoplasm has a cure rate of over 95%; as a result, a major concern is the future of fertility of carriers from this disease. There are several histological subtypes of testicular tumors; however, the Testicular Germ Cell Tumors (TGCTs), comprising both seminoma and non-seminoma tumors, are considered the main subtypes of testicular neoplasms. TGCT are characterized by being a solid tumor that mostly affects young men aged between 15 and 40 years old. While TGCT subtypes may have an invasive potential, seminoma subtype does not affect other cells rather than germ cells, while non-seminomas have more invasive properties and can achieve somatic cells; thus, having a more aggressive nature. This research intends to review the literature regarding information about sperm parameters, correlating the data found in those studies to the subfertility and infertility of patients with TCGTs. Furthermore, it will also correlate the data to the non-seminoma and seminoma histological subtypes from pre- and post-cancer therapy. PubMed databases were used. Searched keywords included: seminoma AND non-seminoma; male infertility; germ cell tumor; chemotherapy AND radiotherapy. Only articles published in English were considered. Current studies demonstrate that both TGCT subtypes promote deleterious effects on semen quality resulting in decreased sperm concentration, declined sperm total motility and an increase in the morphology alterations. However, findings suggest that the non-seminoma subtype effects are more pronounced and deleterious. More studies will be necessary to clarify the behavior of seminoma and non-seminoma tumors implicating the reproductive health of male patients.


Subject(s)
Humans , Male , Adolescent , Adult , Young Adult , Testicular Neoplasms/therapy , Seminoma , Neoplasms, Germ Cell and Embryonal/therapy , Spermatozoa , Semen Analysis
2.
Int. braz. j. urol ; 46(5): 725-740, Sept.-Oct. 2020. tab, graf
Article in English | LILACS | ID: biblio-1134221

ABSTRACT

ABSTRACT Purpose: To evaluate whether components of Testicular Dysgenesis Syndrome (TDS) affect testicular germ cell tumor (TGCT) prognosis and oncological outcomes. According to the hypothesis called TDS; undescended testis, hypospadias, testicular cancer and spermatogenic disorders share the same risk factors and have a combined fetal origin. Materials and Methods: We retrospectively evaluated the stages and oncological outcomes of 69 patients who underwent radical orchiectomy between January 2010 and December 2014 due to TGCT in our department. The presence of undescended testis, hypospadias and semen parameters disorders were recorded according to anamnesis of patients. Results: Among 69 patients with TGCT, only 16 (23.1%) had TDS. Significantly higher rate of TDS (36.1% vs. 9.1%) was observed at the advanced stages of TGCT(p=0.008). In the TDS group, the rates of local recurrence (50% vs. 11.3%, p<0.001), distant metastasis (93.6% vs. 3.8%, p<0.001) and cancer-spesific mortality (87.5% vs. 3.8%, p<0.001) were found significantly higher than those without TDS. The predicted time for recurrence-free survival (13.70±5.13 vs. 100.96±2.83 months, p<0.001) metastasis-free survival (13.12±4.21 vs. 102.79±2.21 months, p <0.001) and cancer-specific survival (13.68±5.38 vs. 102.80±2.19 months, p<0.001) were also statistically lower in this group. Conclusions: According to our preliminary results, there is an apparent relationship between TDS and tumor prognosis. Even if the components of TDS alone did not contain poor prognostic features for TGCT, the presence of TDS was found as the most important independent predictive factor for oncological outcomes in both seminomas and nonseminomas as well as all patients with TGCT.


Subject(s)
Humans , Male , Testicular Diseases/etiology , Testicular Neoplasms/therapy , Neoplasms, Germ Cell and Embryonal/therapy , Prognosis , Testis , Retrospective Studies , Treatment Outcome , Neoplasm Recurrence, Local
4.
Rev. colomb. cancerol ; 24(3): 130-139, jul.-set. 2020. graf
Article in Spanish | LILACS | ID: biblio-1144332

ABSTRACT

Resumen El tumor desmoplásico de célula redonda y pequeña (TDCRP) es una patología neoplásica maligna agresiva y poco común. Afecta predominantemente a hombres entre la segunda y tercera década de la vida. Los pacientes que la padecen tienen un pronóstico pobre, con una supervivencia global a 5 años de hasta el 30%. Por lo general se presenta como una masa en la cavidad abdominal, frecuentemente multifocal. Para su tratamiento se recomienda un enfoque multimodal con cirugía, quimioterapia y radioterapia. Poco más de 20 casos de TDCRP a nivel testicular/paratesticular se han reportado en la literatura. A continuación, se presenta un caso ilustrativo en esta localización, se discute el caso y se realiza revisión de la literatura.


Abstract Desmoplastic small round cell tumor (DSRCT) is an aggressive and rare malignant neoplasm. It mainly affects young men in their twenties and thirties. Patients with it have a poor prognosis, with a 5-year survival rate of up to 30%. It generally presents as a mass in the abdominal cavity, often multifocal. A multimodal approach is recommended for its treatment, with surgery, chemotherapy, and radiotherapy. Just over 20 cases of testicular/paratesticular DSRCT have been reported in the literature. Below, we present an illustrative case in this location, we discuss the case and review the literature.


Subject(s)
Humans , Male , Adult , Retroperitoneal Neoplasms/diagnosis , Retroperitoneal Neoplasms/therapy , Desmoplastic Small Round Cell Tumor/diagnosis , Desmoplastic Small Round Cell Tumor/therapy , Genital Neoplasms, Male/diagnosis , Genital Neoplasms, Male/therapy , Testicular Neoplasms/diagnosis , Testicular Neoplasms/therapy , Ganglia
5.
Int. braz. j. urol ; 46(supl.1): 79-85, July 2020. tab
Article in English | LILACS | ID: biblio-1134298

ABSTRACT

ABSTRACT Introduction: There is little information on how to prioritize testis cancer (TC) patients' care during COVID-19 pandemic in order to relieve its pressure on the health care systems. Objective: To describe the recommendations for diagnosis, treatment and follow-up of patients with TC amidst COVID- 19 pandemic. Material and Methods: Pubmed search and review of the main urological association guidelines on TC. Results: The biology of TC requires immediate care of patients during diagnosis, initial surgical therapy and management of recurrent disease. Active surveillance is the first choice of management and should be offered to all compliant clinical stage I TC patients provided they understand the need to self-isolate. Active surveillance may also help decrease the demand for intensive care unit beds, ventilators, personal protective equipment, and other critical hospital and human resources by minimizing surgeries without compromising patient outcomes. Complications of therapy and symptomatic patients represent medical emergencies and should be treated immediately. Telemedicine may be useful during follow-up periods. Conclusions: Most stages of testis cancer require urgent care; however, all recommendations must be adapted to local health care priorities considering that most of these patients are at low risk of severe COVID-19 infection.


Subject(s)
Humans , Male , Pneumonia, Viral/epidemiology , Testicular Neoplasms/therapy , Coronavirus Infections/epidemiology , Pandemics , Betacoronavirus , SARS-CoV-2 , COVID-19
6.
Int. braz. j. urol ; 45(3): 629-633, May-June 2019. graf
Article in English | LILACS | ID: biblio-1012332

ABSTRACT

Abstract Most patients with testicular germ cell tumor present with a painless scrotal mass. We report a 19-year-old patient who presented with neurological complains. Rapid clinical progression to coma was noted during the staging work up. A diagnosis of testicular mixed germ cell tumor with multiorgan metastasis (lymph node, lung, liver and brain) was made. Patients with brain metastasis should receive chemotherapy alone or combined with surgery or radiotherapy. Because the clinical symptoms deteriorated quickly, surgery was used upfront followed by chemotherapy and radiotherapy for the brain tumor. After the first stage of treatment, the clinical symptoms, tumor markers and imaging findings were improved. The residual brain tumor was eliminated by chemotherapy, and only sparse degenerated tumor cells were noted in the brain tissue. Longer follow up is required to assess the impact of our treatment strategy.


Subject(s)
Humans , Male , Young Adult , Seizures/pathology , Testicular Neoplasms/pathology , Brain Neoplasms/secondary , Neoplasms, Germ Cell and Embryonal/secondary , Seizures/diagnostic imaging , Testicular Neoplasms/therapy , Testicular Neoplasms/diagnostic imaging , Time Factors , Brain Neoplasms/therapy , alpha-Fetoproteins/analysis , Tomography, X-Ray Computed , Neoplasms, Germ Cell and Embryonal/therapy , Neoplasms, Germ Cell and Embryonal/diagnostic imaging , Chorionic Gonadotropin, beta Subunit, Human/blood , L-Lactate Dehydrogenase/blood
7.
Int. braz. j. urol ; 45(1): 74-82, Jan.-Feb. 2019. tab, graf
Article in English | LILACS | ID: biblio-989965

ABSTRACT

ABSTRACT Purpose: The current first - line treatment for non - seminomatous germ cell tumor (NSGCT) consists of four cycles of cisplatin, etoposide, and bleomycin (BEP), which results in 5 - year overall survival < 60% in patients with poor - risk features. Autologous hematopoietic stem cell transplantation (auto - HSCT) as a method for overcoming high toxicity after high dose chemotherapy (HDC) has been explored in different solid tumors, but has remained standard practice only for NSGCT. Our objective was to describe outcomes of patients with poor - risk NSGCT who underwent first - line autologous HSCT in a tertiary center in Mexico. Patients and Methods: Twenty nine consecutive patients with NSGCT who received first - line, non - cryopreserved autologous HSCT at the National Institute of Medical Sciences and Nutrition Salvador Zubiran in Mexico City, Mexico, from November 1998 to June 2016, were retrospectively analyzed. Results: The median age at transplantation was 23 (15 - 39) years. Most patients (n = 18, 62%) had testicular primary tumor, and 23 had metastases (79%). Complete response after auto - HSCT was observed in 45%. Non - relapse mortality was 0. Five - year relapse / progression free and overall survival were 67% and 69%, respectively. Conclusions: This small single limited - resource institution study demonstrated that patients with poor - risk NSGCT are curable by first - line HDC plus autologous HSCT and that this procedure is feasible and affordable to perform using non - cryopreserved hematopoietic stem cells.


Subject(s)
Testicular Neoplasms/therapy , Bleomycin/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Cisplatin/administration & dosage , Neoplasms, Germ Cell and Embryonal/therapy , Hematopoietic Stem Cell Transplantation/methods , Etoposide/administration & dosage , Retrospective Studies , Treatment Outcome , Combined Modality Therapy , Kaplan-Meier Estimate
8.
Einstein (Säo Paulo) ; 15(4): 496-499, Oct.-Dec. 2017. graf
Article in English | LILACS | ID: biblio-891429

ABSTRACT

ABSTRACT Germ cell tumors are rare neoplasms that mostly occur in the gonads, although they can also affect other body sites, especially the anterior mediastinum (50 to 70% of all extragonadal germ cell tumors). We report a case of a primary mediastinal yolk sac tumor, a rare and aggressive germ cell tumors subtype. This was a 38-year-old man who was admitted to Hospital do Servidor Público Estadual "Francisco Morato de Oliveira", complaining about dyspnea and dry cough for 1 year. The computed tomography scan of his chest revealed a large mass in the anterior mediastinum with heterogeneous enhancement to the contrast associated with pleural effusion. There were also high serum levels of alpha-fetoprotein. After neoadjuvant chemotherapy, the patient underwent surgical resection of the mass, followed by pathological examination, which confirmed a primary mediastinal yolk sac tumor, a nonseminomatous subtype of germ cell tumors. Primary mediastinal yolk sac tumors have poor prognosis, despite advances in therapy with surgical resection and cisplatin-based chemotherapy. This poor prognosis is due to the degree of invasion and unresectability in most patients by the time of the diagnosis.


RESUMO Os tumores de células germinativas são neoplasias raras que acometem mais frequentemente as gônadas, embora possam também ocorrer em outras localizações do corpo, destacando-se o mediastino anterior (50 a 70% de todos os tumores de células germinativas extragonadais). No presente artigo, relatamos um caso de tumor de saco vitelínico mediastinal primário, de subtipo raro e agressivo de tumor de células germinativas. Tratava-se de um homem, 38 anos, admitido no Hospital do Servidor Público Estadual "Francisco Morato de Oliveira", com quadro de dispneia e tosse seca há 1 ano. Na investigação clínica, foi solicitada tomografia computadorizada de tórax, que mostrou volumosa massa no mediastino anterior com realce heterogêneo ao meio de contraste associada a derrame pleural. Havia ainda aumento dos níveis séricos da alfafetoproteína. Após quimioterapia neoadjuvante pré-operatória, o paciente foi submetido à ressecção cirúrgica, seguida de estudo anatomopatológico da peça, no qual demonstrou tratar-se de um tumor de saco vitelínico primário do mediastino. Os tumores de saco vitelínicos primários do mediastino têm prognóstico reservado, apesar do avanço na terapêutica com a ressecção cirúrgica e a quimioterapia à base de cisplatina. Isto se deve ao grau de invasão e de irressecabilidade na maioria dos pacientes no momento do diagnóstico.


Subject(s)
Humans , Male , Adult , Testicular Neoplasms/therapy , Endodermal Sinus Tumor/therapy , Neoplasms, Germ Cell and Embryonal/therapy , Neoadjuvant Therapy , Mediastinal Neoplasms/therapy , Testicular Neoplasms/pathology , Testicular Neoplasms/diagnostic imaging , Thoracotomy , alpha-Fetoproteins/analysis , Tomography, X-Ray Computed , Endodermal Sinus Tumor/pathology , Endodermal Sinus Tumor/diagnostic imaging , Neoplasms, Germ Cell and Embryonal/diagnosis , Neoplasms, Germ Cell and Embryonal/pathology , Mediastinal Neoplasms/pathology , Mediastinal Neoplasms/diagnostic imaging , Mediastinum/diagnostic imaging
9.
Rev. chil. cir ; 69(5): 416-420, oct. 2017. ilus
Article in Spanish | LILACS | ID: biblio-899627

ABSTRACT

Resumen Introducción: El hematoma retroperitoneal (HR) es una enfermedad infrecuente con una elevada morbimortalidad, siendo complicado cuando se presenta con dolor y shock hipovolémico. Presentación del caso: Paciente del sexo masculino, de 20 años de edad, sin antecedentes mórbidos. Ingresa en Urgencias por dolor abdominal en el flanco izquierdo, irradiado a dorso y testículo ipsilateral, de 6 h de evolución, de inicio súbito e intensidad severa; el paciente está pálido, hemodinámicamente estable, sin signos de irritación peritoneal. Se solicita pielo-TC por sospecha de litiasis ureteral, que muestra un extenso HR, probable aneurisma aórtico roto. Una angio-TC informa HR adyacente y anterior a psoasilíaco izquierdo, de20 × 11 × 8,5 cm, volumen 972 cc, adenopatías retroperitoneales paraaórticas bilaterales sangrantes y múltiples nódulos pulmonares bilaterales indicativos de diseminación secundaria. Se constata testículo derecho duro, de tamaño normal, eco testicular con masa sólida quística, que indica de lesión orgánica. Discusión: Trauma y enfermedad tumoral son las principales causas de HR. El cáncer testicular suele presentarse en pacientes jóvenes, requiriendo una pronta derivación y estudio debido a su rápida progresión. En nuestro caso, el HR fue un hallazgo imagenológico, destacando que el sangrado de un conglomerado de adenopatías es anecdótico.


Abstract Introduction: Retroperitoneal hematoma (RH) is a rare disease with high morbidity, being complicated when presented with pain and hypovolemic shock. Case report: Male, 20 years old, no morbid history. Arrive to Emergency Service for abdominal pain in the left flank radiating to the back and ipsilateral testis, 6 h of evolution, sudden onset, high intensity; pacient pale, hemodynamically stable without signs of peritoneal irritation. Pielo-TC is requested on suspicion of ureteral stones showing extensive RH, likely ruptured aortic aneurysm. CT angiography reports RH and adjacent preceding left iliopsoas, 20 × 11 × 8.5 cm, volume 972 cc, retroperitoneal bleeding bilateral para-aortic lymphadenopathy and multiple bilateral pulmonary nodules suggestive of secondary spread. Hard right testicle with normal size, testicular ultrasound pointing solid cystic mass, suggestive of organic lesion. Discussion: Trauma and tumor pathology are the main causes of RH. Testicular cancer usually occurs in young patients, requiring early referal and study because of its rapid progression. In our case, the HR was an imaging finding, highlighting that the bleeding of a cluster of lymph nodes is anecdotal.


Subject(s)
Humans , Male , Young Adult , Retroperitoneal Space , Testicular Neoplasms/complications , Carcinoma, Embryonal/complications , Hematoma/etiology , Hematoma/diagnostic imaging , Testicular Neoplasms/therapy , Testicular Neoplasms/diagnostic imaging , Abdominal Pain/etiology , Carcinoma, Embryonal/therapy , Carcinoma, Embryonal/diagnostic imaging , Computed Tomography Angiography
11.
Rev. chil. urol ; 78(1): 8-13, 2013.
Article in Spanish | LILACS | ID: lil-773999

ABSTRACT

Los tumores testiculares de células germinales (TCG) son poco frecuentes, corresponden al 2 por ciento de todos los cánceres masculinos. La incidencia de cáncer contralateral oscila entre 1por ciento a 5 por ciento, siendo los tumores metacrónicos mucho más comunes que los sincrónicos bilaterales. El tratamiento estándar en estos casos es la orquidectomía bilateral. Se han propuesto diferentes enfoques que buscan preservar la función testicular. Dentro de estas alternativas se describen en la literatura la Orquidectomía Parcial (OP), el Ultrasonido Focalizado de Alta Intensidad (HIFU por su sigla en inglés) y la radioterapia primaria. Nuestro objetivo es realizar una revisión de este tema y describir las alternativas de tratamiento a la orquidectomía radical, con la idea de preservar la función androgénica. Para esto nos enfocaremos en el manejo del paciente con masa testicular palpable, no palpable y sus alternativas terapéuticas.


Testicular germ cell tumors (GCT) are rare, corresponding to 2 percent of all male cancers. Contralateral cancer incidence ranges from 1 percent to 5 percent, metachronous tumors being more common than bilateral synchronous. Standard treatment in these cases is bilateral orchiectomy. Diferent approaches have been proposed that seek to preserve testicular function. Among these alternatives the literature describes Partial orchiectomy (OP), High Intensity Focused Ultrasound (HIFU for its acronym in English) and primary radiotherapy. Our goal is to review this issue and describe treatment alternatives to radical orchiectomy, with the idea of preserving androgenic function. We focus on the management of patients with palpable testicular mass, not palpable mass and it therapeutic alternatives.


Subject(s)
Humans , Male , Testicular Neoplasms/therapy , Neoplasms, Germ Cell and Embryonal/therapy , Orchiectomy/methods , Radiotherapy , High-Intensity Focused Ultrasound Ablation , Combined Modality Therapy
12.
Rev. chil. urol ; 77(2): 146-149, 2012. ilus, graf
Article in Spanish | LILACS | ID: lil-783402

ABSTRACT

El linfoma testicular es una patología infrecuente, correspondiendo al 9 por ciento de los cánceres testiculares, presentándose más frecuentemente entre los 60 a 80 años (25-50 por ciento). La presentación clínica más frecuente es el aumento de volumen unilateral e indo/oro. El tipo histológico más común es linfoma difuso de células grandes B (60-90 por ciento). La orquidectomía radical asociada a quimioterapia y radioterapia es la primera línea de tratamiento para los pacientes con enfermedad limitada. Material y método: Estudio retrospectivo descriptivo. Se revisó y filtró la lista de pacientes ingresados al SIGGES como tumor testicular entre enero 2005 a abril 2011. De los pacientes con diagnóstico histológico e inmunohistoquímico compatible, se registraron las características epidemiológicas, estudio, manejo y sobrevida. Posteriormente se realizó un análisis de la base de datos con el programa estadístico SPSS 13. 0. Resultados: De un total de 299 pacientes con el diagnóstico histológico de cáncer testicular, 8 pacientes fueron diagnosticados como linfoma testicular confirmado por histología e inmunohistoquímica. El promedio y mediana de edad fue 52 años y 63 años (18-73) respectivamente. Tres casos (37,5 por ciento) correspondieron a presentaciones secundarias. En 6 de los casos (75 por ciento) el testículo afectado fue el derecho. Histológicamente, el 63 por ciento correspondió a Linfoma difuso de células grande B. Clínicamente, el todos los casos se presentaron con aumento de volumen y con marcadores en rango normal. En 7 casos (8 7, 5 por ciento) el diagnóstico y manejo inicial fue mediante orquidectomía radical, y en un caso por biopsia testicular, con orquidectomía posterior 3 casos presentaron diseminación...


esticular lymphoma is a rare disease, happening in 9 percent of testicular cancers, most commonly between the ages 60 to 80 years (25 percent-50 percent). The most common presentation is unilateral indolent testicular growth. Histology shows a diffuse big B cell lymphoma in most of the cases (60 percent-90 percent). Radical orchiectomy, chemotherapy and radiation are the first line therapy for patients with limited disease. Materials and methods: Retrospective clinical study. We included and filtered the SIGGES list of patients admitted for Testicular Tumor from January 2005 to April 2011. Patients with a compatible diagnosis were analyzed, using SPSS 13.0® as statistical software. Result: Of a total number of 299 testicular cancer patients 8 presented with a histological and inmunnohistochemical testicular lymphoma. Mean age was 52 years and the median 63 years (18-73). ln three cases (37.5 percent) it was a secondary localization. ln 6 cases ( 75 percent) the affected testicle was the right one. 63 percent corresponded to a diffuse big cell B cell Lymphoma. All patients presented normal tumor markers. ln 7 (87,5 percent) cases the initial treatment was radical orchiectomy in one patient the diagnosis was don through a testicular biopsy, and the orchidectomy was differed. 3 cases presented dissemination. In 7 patients adjuvant chemotherapy was performed. Mortal/ty was 38 percent with a 1 7-month follow-up. Conclusion: Testicular lymphoma is a rare condition with bad prognosis. Histology is fundamental for treatment, an in this sense inmunohystochemcal analysis is especially helpful...


Subject(s)
Humans , Male , Adolescent , Adult , Middle Aged , Young Adult , Lymphoma/epidemiology , Lymphoma/pathology , Testicular Neoplasms/epidemiology , Testicular Neoplasms/pathology , Epidemiology, Descriptive , Neoplasm Staging , Retrospective Studies , Follow-Up Studies , Incidence , Immunohistochemistry , Lymphoma/therapy , Testicular Neoplasms/therapy
13.
São Paulo med. j ; 129(5): 346-351, 2011. ilus, tab
Article in English | LILACS | ID: lil-604795

ABSTRACT

CONTEXT: Synthesis of cortisol and aldosterone is impaired in patients with congenital adrenal hyperplasia (CAH) because of 21-hydroxylase deficiency. Men with CAH have low fertility rates compared with the normal population, and this is related to testicular adrenal rest tumors. Findings of azoospermia in combination with a testicular tumor on ultrasound are likely to have a mechanical cause, especially when in the testicular mediastinum. The preferred treatment method consists of intensive corticoid therapy. However, when the tumor is unresponsive to steroid therapy, surgical treatment should be considered. CASE REPORT: We present the case of a male patient with CAH due to 21-hydroxylase deficiency who presented a testicular tumor and azoospermia. Treatment with low daily corticoid doses had previously been started by an endocrinologist, but after 12 months, no significant change in sperm count was found. Although the adrenocorticotrophic hormone and 17-hydroxyprogesterone levels returned to normal values, the follicle-stimulating hormone (FSH), luteinizing hormone and testosterone levels remained unchanged. Ultrasound examination confirmed that the testicles were small and heterogenous bilaterally, and revealed a mosaic area at the projection of the testis network bilaterally. Magnetic resonance imaging confirmed the finding. Testicular biopsy revealed the presence of preserved spermatogenesis and spermiogenesis in 20 percent of the seminiferous tubules in the right testicle. The patient underwent testis-sparing tumor resection. After 12 months of follow-up, there was no tumor recurrence but the patient still presented azoospermia and joined an intracytoplasmic sperm injection program.


CONTEXTO: Pacientes com hiperplasia adrenal congênita (HAC) por deficiência da 21-hidroxilase podem ter a síntese de cortisol e de aldosterona prejudicada. Homens com HAC têm baixas taxas de fertilidade em comparação com a população normal, e isso está relacionado a tumores testiculares de remanescente adrenal. A associação de azoospermia e tumor testicular sugere uma causa mecânica, principalmente quando o tumor é encontrado no mediastino testicular. O método preferencial de tratamento consiste na corticoterapia intensa. No entanto, quando o tumor não é responsivo à terapia com esteroides, o tratamento cirúrgico deve ser considerado. RELATO DE CASO: Apresentamos o caso de um paciente do sexo masculino com HAC por deficiência da 21-hidroxilase, portador de tumor testicular e azoospermia. Em consulta prévia com endocrinologista, o paciente começou tratamento com baixas doses diárias de corticoide, porém, após 12 meses de tratamento, não houve mudança significativa no espermograma. Embora os níveis de hormônio adrenocortitrófico e 17-hidroxiprogesterona tenham se normalizado, os níveis séricos de hormônio folículo-estimulante, hormônio luteinizante e testosterona não se alteraram. Exame ultrassonográfico confirmou testículos bilateralmente diminuídos e heterogêneos, além de área em mosaico na projeção da rede testis bilateralmente. Ressonância nuclear magnética confirmou o achado. Biópsia testicular revelou espermatogênese e espermiogênese preservadas em 20 por cento dos túbulos seminíferos no testículo direito. O paciente foi submetido a cirurgia poupadora testicular, com ressecção tumoral. Após 12 meses de acompanhamento, não houve recorrência tumoral, mas o paciente ainda apresentava azoospermia, sendo integrado no programa de injeção intracitoplasmática de espermatozoides.


Subject(s)
Adult , Humans , Male , Adrenal Hyperplasia, Congenital/diagnosis , Adrenal Rest Tumor/diagnosis , Azoospermia , Testicular Neoplasms/diagnosis , Adrenal Hyperplasia, Congenital/complications , Adrenal Rest Tumor/therapy , Azoospermia/etiology , Magnetic Resonance Imaging , Testicular Neoplasms/therapy , Testis/pathology , Treatment Outcome
14.
Indian J Cancer ; 2010 Apr-June; 47(2): 134-138
Article in English | IMSEAR | ID: sea-144317

ABSTRACT

Background : Relapse of disease is documented in 15-20% of children with acute lymphoblastic leukemia (ALL). Although testicular relapse is rare with modern risk-adapted treatment protocols, earlier, the testes were a frequently encountered site of relapse and were designated as "drug sanctuaries". Purpose : This descriptive study was designed to assess the pattern of testicular relapse and to identify high-risk factors. Materials and Methods : Data obtained from case records of 407 boys with ALL were analyzed. Fine needle aspiration cytology was carried out in children presenting with painless enlargement of testi(e)s. Bone marrow aspiration and cerebrospinal fluid examination were performed concomitantly to confirm or exclude disease at these sites. Results : Testicular relapse was documented in 30 boys. It was isolated in 17 patients and associated with bone marrow and/or central nervous system relapse in 13. At relapse, nine boys were over the age of 10 years. The majority were very early and early relapsers. Hyperleucocytosis was documented in five of 30 and seven of 137 relapsers and nonrelapsers, respectively (P = 0.04). Twelve of the 30 boys with testicular relapse were treated with testicular irradiation, reinduction and maintenance therapy. The estimated median overall survival was 33 months. Conclusion : Testicular relapse, which depends on the therapy administered, may manifest several months/years after completion of treatment. The high incidence of testicular relapse in our series implicates the need of revaluation of our protocol and incorporation of high/intermediate dose methotrexate therapy upfront.


Subject(s)
Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Asparaginase/administration & dosage , Brain Neoplasms/therapy , Child , Child, Preschool , Combined Modality Therapy , Cranial Irradiation , Humans , Infant , Male , Methotrexate/administration & dosage , Neoplasm Recurrence, Local/therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Prednisolone/administration & dosage , Survival Rate , Testicular Neoplasms/therapy , Treatment Outcome , Vincristine/administration & dosage
15.
Indian J Cancer ; 2010 Apr-June; 47(2): 93-94
Article in English | IMSEAR | ID: sea-144311
17.
Int. braz. j. urol ; 35(2): 190-198, Mar.-Apr. 2009. tab
Article in English | LILACS | ID: lil-516966

ABSTRACT

PURPOSE: Report the characteristics of cryopreserved semen from a cohort of male cancer patients, attitudes towards cryopreservation and outcomes of semen samples based on a 12-year cryopreservation program. MATERIAL AND METHODS: Data from 98 male cancer patients whose sperm samples were banked were evaluated. Demographic parameters, semen characteristics, destination of sperm banked samples and questionnaires answered by the patients regarding cryopreservation time were evaluated. RESULTS: The cancer diagnoses were testicle (56.1 percent), prostate (15.3 percent), Hodgkin’s lymphomas (9.2 percent), non-Hodgkin’s lymphomas (7.1 percent), leukemia (3.1 percent) and other malignancies (9.2 percent). The patients with testicular cancer presented lower sperm concentration (p < 0.001); however, there were no differences with the percentage of normozoospermic patients among cancer type groups (p = 0.185). A shorter time between cancer diagnosis and sperm banking was observed for testicular and prostate cancer patients (p < 0.001). Most of the patients (89.5 percent) favored sperm banking as a fertility preservation method. CONCLUSIONS: Although less than 20 percent of banked sperm samples were disposed of, the majority of patients related sperm banking with safe for fertility preservation. Our results show that all male cancer patients of reproductive age facing cancer treatment could be offered sperm banking.


Subject(s)
Adolescent , Adult , Aged , Humans , Male , Middle Aged , Young Adult , Cryopreservation/statistics & numerical data , Infertility, Male/prevention & control , Neoplasms , Sperm Banks , Semen Preservation/statistics & numerical data , Attitude to Health , Epidemiologic Methods , Infertility, Male/chemically induced , Neoplasms/therapy , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/therapy , Radiotherapy/adverse effects , Semen Analysis , Sperm Banks , Testicular Neoplasms/diagnosis , Testicular Neoplasms/therapy , Young Adult
18.
Rev. chil. urol ; 74(1): 15-19, 2009. tab, graf
Article in Spanish | LILACS | ID: lil-562703

ABSTRACT

Introducción: Los tumores testiculares germinales son la neoplasia maligna más frecuente en hombres jóvenes. La incidencia varía por región geográfica. Es altamente curable. El objetivo de este trabajo fue caracterizar a los pacientes y calcular la tasa de incidencia. Materiales y método: Se realizó un estudio descriptivo retrospectivo de 136 fichas clínicas en el período 2003-2008.Resultados: La edad promedio fue de 32,8 años. Un 57 por ciento correspondieron a seminoma, 28 por ciento no seminoma y 14 por ciento mixtos. Un 8 por ciento fueron bilaterales. La tasa fue de 11 por 100.000 habitantes mayores de 15 años. Conclusiones: La mayoría de nuestros datos fueron concordantes con lo descrito en otras publicaciones. La incidencia de cáncer testicular es mayor a la descrita en otras regiones de Chile y del mundo.


Backgrounds: Germ cell tumors of the testicle are the most frequent malignant neoplasm in young men. The incidence varies between geographical regions. This neoplasm is highly curable. The objective of this study was to characterize the patients and calculate the incidence rate. Methods: A descriptive retrospective study was performed with 136 medical histories in the 2003-2008 period. Results: The average age was 32.8 years. 57 percent corresponded to seminomas, 28 percent to non-seminomas and 14 percent were mixed germ cell tumors.8 percent were bilateral. The rate was 11 per 100.000 inhabitants over 15 years. Conclusions: The majority of our results were similar to those described in other publications. The incidence of testicular cancer is higher than the incidence described in other regions of Chile and the world.


Subject(s)
Humans , Male , Adolescent , Adult , Middle Aged , Testicular Neoplasms/epidemiology , Testicular Neoplasms/pathology , Age Distribution , Neoplasm Staging , Retrospective Studies , Incidence , Testicular Neoplasms/therapy
20.
São Paulo med. j ; 125(5): 286-288, Sept. 2007.
Article in English | LILACS | ID: lil-470626

ABSTRACT

Primary testicular non-Hodgkin's lymphoma was first described as a clinical entity in 1866. It is a rare disease and accounts for 1 percent of all non-Hodgkin's lymphoma, 2 percent of all extranodal lymphomas and 5 percent of all testicular neoplasms. It is the most common testicular tumor in males between sixty and eighty years of age. Testicular non-Hodgkin's lymphoma is unique in its high incidence of bilateral involvement (8-38 percent), and it is also the most common bilateral testicular tumor. Testicular non-Hodgkin's lymphoma has a predilection for spreading to non-contiguous extranodal sites, especially the central nervous system. Advanced-stage disease is usually managed with doxorubicin-based chemotherapy. For early-stage disease, opinion is divided regarding systemic chemotherapy following orchidectomy. The high incidence of spreading, especially to the central nervous system, leads to advocacy of the use of central nervous system prophylaxis with intrathecal chemotherapy. Prospective multicenter trials incorporating a large number of patients may lead to better guidelines for optimal management of this subtype of non-Hodgkin's lymphoma.


O linfoma primário do testículo (LPT) foi descrito como uma entidade clínica pela primeira vez em 1866. É uma doença rara e corresponde a 1 por cento de todos os linfomas não-Hodgkin, 2 por cento de todos os linfomas extranodais e 5 por cento de todos as neoplasias testiculares. É o tumor testicular mais comum em homens entre 60 e 80 anos de idade. LPT é único em sua elevada incidência de envolvimento bilateral (8-38 por cento), sendo o tumor testicular bilateral mais comum. Tem uma predileção por disseminação para regiões extranodais não-contíguas, especialmente para o sistema nervoso central (SNC). Estágios avançados da doença são usualmente tratados com quimioterapia à base de doxorubicina. Para os estágios mais precoces, as opiniões são divergentes quanto à quimioterapia associada à orquiectomia. A alta prevalência de disseminação, especialmente para o SNC, sugere o uso de quimioterapia intratecal como profilaxia. Estudos prospectivos multicêntricos incluindo um grande número de pacientes poderiam resolver a questão com relação ao manejo deste subtipo de linfoma não-Hodgkin.


Subject(s)
Humans , Male , Lymphoma, Non-Hodgkin/therapy , Testicular Neoplasms/therapy , Central Nervous System Neoplasms/prevention & control , Doxorubicin/therapeutic use , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/etiology , Orchiectomy , Testicular Neoplasms/complications , Testicular Neoplasms/etiology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL